Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of medical research and bioethics experts at Oxford University are supporting several European governments to explore the feasibility of a coronavirus mobile app for instant contact tracing. If rapidly and widely deployed, the infectious disease experts believe such an app could significantly help to contain the spread of coronavirus.

Stethoscope and mobile phone

The Oxford University team has provided European governments, including the UK, with evidence to support the feasibility of developing a contact tracing mobile app that is instant, could be widely deployed, and should be implemented with appropriate ethical considerations. The Oxford University team recommends that the mobile application should form part of an integrated  coronavirus control strategy that identifies infected people and their recent person-to-person contacts using digital technology.

Professor Christophe Fraser from Oxford University’s Big Data Institute, Nuffield Department of Medicine, explains why a contact tracing app could be deployed with urgency: 'Coronavirus is unlike previous epidemics and requires multiple inter-dependent containment strategies. Our analysis suggests that almost half of coronavirus transmissions occur in the very early phase of infection, before symptoms appear, so we need a fast and effective mobile app for alerting people who have been exposed. Our mathematical modelling suggests that traditional public health contact tracing methods are too slow to keep up with this virus.'

Professor Fraser continues, 'The instant mobile app concept is very simple. If you are diagnosed with coronavirus, the people you’ve recently come into contact with will be messaged advising them to isolate. If this mobile app is developed and deployed rapidly, and enough people opt-in to use such an approach, we can slow the spread of coronavirus and mitigate against devastating human, economic and social impacts.'

Read the full story on the University of Oxford website

Watch the recent Channel 4 interview with Professor Christophe Fraser and Dr David Bonsall

Similar stories

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Retirement of Professor Peter Brown

General

This month sees the retirement of Professor Peter Brown as Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford.

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.